OBI Pharma Showcases Advancements in Glycan-Based ADCs at AACR 2026

Ten poster presentations highlight the transformative potential of the company's GlycOBI® platform for next-generation antibody-drug conjugates.

Apr. 15, 2026 at 10:53am

Got story updates? Submit your updates here. ›

An abstract illustration featuring glowing, vibrant neon lines outlining the shape of a molecular structure or medical device, conveying the innovative and high-tech nature of OBI Pharma's antibody-drug conjugate technology.Glowing neon outlines capture the energy and precision of OBI Pharma's next-generation antibody-drug conjugates, designed to target tumors more effectively while reducing side effects.San Diego Today

OBI Pharma, Inc. announced its presence at the AACR 2026 Annual Meeting, highlighted by ten poster presentations showcasing the latest advancements on its glycan-based site-specific antibody-drug conjugate (ADC) technologies, including mono and bi-specific ADCs as well as dual-payload ADCs. The company's proprietary GlycOBI® and GlycOBI DUO® platforms enable the generation of highly homogeneous ADCs with improved pharmacokinetic profiles and reduced off-target toxicity.

Why it matters

OBI's glycan-based ADC technologies address key limitations of conventional ADCs, such as heterogeneous drug-to-antibody ratios, suboptimal stability, and narrow therapeutic windows. By developing next-generation ADCs that target multiple antigens and deliver dual payloads, OBI aims to overcome tumor heterogeneity and drug resistance, providing more effective and durable treatment options for patients with difficult-to-treat solid tumors.

The details

The ten poster presentations at AACR 2026 will highlight OBI's lead ADC programs, including anti-TROP2 (OBI-902) and anti-Nectin-4 (OBI-904) ADCs, as well as bispecific ADCs targeting TROP2/HER2 (OBI-201) and cMET/HER3 (OBI-221). The data will demonstrate the improved pharmacokinetic profiles, enhanced cytotoxicity, and ability to overcome drug resistance associated with OBI's glycan-based ADC technologies. Additionally, OBI will present its novel Obrion™ ADC enabling platforms, such as the ThiOBI® irreversible cysteine conjugation technology and the GlycOBI DUO® dual-payload approach.

  • The AACR 2026 Annual Meeting will take place from April 17 to 22, 2026 in San Diego, California.
  • The poster presentations will be available for browsing on the AACR virtual meeting platform starting at 12:00 PM PT on April 17, 2026, and on the OBI Pharma website beginning on April 18, 2026.

The players

OBI Pharma, Inc.

A clinical-stage global oncology company headquartered in Taiwan, dedicated to developing innovative cancer therapeutics, including next-generation antibody-drug conjugates.

Dr. Ya-Chi Chen

Chief Scientific Officer of OBI Pharma, leading the company's efforts to deliver better ADCs that target tumors more effectively and precisely while reducing side effects.

Got photos? Submit your photos here. ›

What they’re saying

“At OBI, we make better ADCs. Our goal is to deliver therapies that not only target tumors more effectively and precisely, but also reduce side effects, giving patients potentially life-changing treatment options.”

— Dr. Ya-Chi Chen, Chief Scientific Officer, OBI Pharma

What’s next

OBI Pharma's lead ADC programs, OBI-902 and OBI-904, are currently in Phase 1/2 clinical trials, with completion of the Phase 1a portion targeted for the first half of 2027.

The takeaway

OBI Pharma's innovative glycan-based ADC technologies, including the GlycOBI® and GlycOBI DUO® platforms, have the potential to overcome the limitations of conventional ADCs and provide more effective and durable treatment options for patients with difficult-to-treat solid tumors.